Oncology

Showing 15 posts of 308 posts found.

First patient dosed in Transgene and BioInvent’s phase 1 trial

October 10, 2023
Research and Development BioInvent, Oncology, Transgene, oncology, phase 1 trial

Transgene and BioInvent have announced that the first patient has been treated in the phase 1 part B clinical trial …

BMS acquires Mirati Therapeutics for $4.8bn

October 9, 2023
Business Services BMS, Mirati Therapeutics, Oncology, acquisition, bristol myers squibb, oncology

Bristol Myers Squibb (BMS) and Mirati Therapeutics have announced that they have entered into a definitive agreement under which BMS …

Eli Lilly to acquire POINT Biopharma

October 4, 2023
Business Services Eli Lilly, Oncology, POINT Biopharma, acquisition, oncology

Eli Lilly and POINT Biopharma have announced a definitive agreement for Lilly to acquire POINT to expand its pipeline of …

FDA grants marketing authorisation to DNA test for predisposition to certain cancers

October 2, 2023
Research and Development FDA, Invitae, Oncology, cancer testing, oncology

The US Food and Drug Administration (FDA) has granted de novo marketing authorisation to the Invitae Common Hereditary Cancers Panel, …

Kura Oncology shares preclinical data for NSCLC treatment

September 29, 2023
Medical Communications Kura Oncology, NSCLC, Oncology, oncology

Kura Oncology has shared positive preclinical data which supports the development of its next-generation farnesyl transferase inhibitor (FTI) KO-2806 in …

AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan performs well in phase 3 trial

September 22, 2023
Research and Development AstraZeneca, Daiichi Sankyo, Oncology, breast cancer, clinical trial

AstraZeneca and Daiichi Sankyo have shared positive high-level results from the TROPION-Breast01 phase 3 trial, which showed datopotamab deruxtecan (Dato-DXd) …

EC approves Menarini Group’s Orserdu for breast cancer treatment

September 21, 2023
Medical Communications European Commission, Oncology, Orserdu, breast cancer

The Menarini Group and its subsidiary Stemline Therapeutics have announced that the European Commission (EC) has approved Orserdu (elacestrant) as …

Exscientia enters AI drug discovery collaboration with Merck KGaA

September 20, 2023
Business Services AI, Exscientia, Immunology, Merck KGaA, Neurology, Oncology, collaboration, drug discovery

Exscientia has announced a new collaboration with Merck KGaA, Darmstadt, Germany, with a focus on the discovery of novel small …

Nuvectis Pharma initiates phase 1a NXP900 clinical trial

September 13, 2023
Research and Development Cancer, Nuvectis Pharma, Oncology, clinical trial

Clinical stage biopharmaceutical company Nuvectis Pharma has announced the initiation of a phase 1a dose escalation clinical study of NXP900, …

AstraZeneca and Daiichi Sankyo share positive results from DESTINY-Lung02 phase 2 trial

September 11, 2023
Medical Communications AstraZeneca, Daiichi Sankyo, Enhertu, NSCLC, Oncology, clinical trial

AstraZeneca and Daiichi Sankyo have announced results from the primary analysis of the DESTINY-Lung02 phase 2 trial, which showed Enhertu’s …

Plus Therapeutics initiates part B of phase 1/2a ReSPECT-LM trial for leptomeningeal metastase

September 6, 2023
Research and Development Oncology, Plus Therapeutics, clinical trial, leptomeningeal metastase

Plus Therapeutics has announced that the first patient has begun treatment in part B of the ReSPECT-LM phase 1/2a dose …

AstraZeneca’s Calquence approved in China for chronic lymphocytic leukaemia treatment

September 4, 2023
Medical Communications AstraZeneca, CLL, China, Oncology, SLL

AstraZeneca has announced that Calquence (acalabrutinib) has been approved in China for the treatment of adult patients with chronic lymphocytic …

lungs

Genentech shares phase 3 results for ALK-positive early-stage lung cancer treatment

September 1, 2023
Research and Development Genentech, NSCLC, Oncology, clinical trials, lung cancer

Roche’s Genentech has announced that the phase 3 ALINA trial assessing Alecensa, compared with platinum-based chemotherapy for the treatment of …

Merck’s Keytruda approved by EC for gastric cancer

August 30, 2023
Research and Development EC, Merck, Oncology, gastric cancer, keytruda

Merck (known as MSD outside of the US and Canada) has announced the approval of its gastric cancer treatment, Keytruda, …

FDA gives Orphan Drug Designation to Faron Pharmaceuticals’ Bexmarilimab

August 29, 2023
Research and Development FDA, Faron, ODD, Oncology, leukemia

Faron Pharmaceuticals announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its …

The Gateway to Local Adoption Series

Latest content